Founded in 1997, Ergomed is a complete, global Phase I-IV clinical development and trial management service partner with leading expertise in developing rare diseases and oncology drugs. Pioneers in rare disease drug development since 1998, Ergomed embody a family & patient-centric approach to recruitment and retention with access to global patients in vital geographical areas. To further strengthen Ergomed CRO’s strong operational footprint, Ergomed invested in a strategic US acquisition of MedSource CRO, fully integrated in early 2021. Ergomed’s fast-growing services business includes an industry-leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO).
Ergomed has supported and managed clinical development, trial management, pharmacovigilance, and medical information services for over 300 clients in more than 100 countries.